Brief: Anaptys Announces Rosnilimab Achieved Positive Results In RA Phase 2B Trial

AnaptysBio

12/02/2025 12:44

Feb 12 (Reuters) - AnaptysBio  ANAB.O :
    * ANAPTYS ANNOUNCES ROSNILIMAB ACHIEVED POSITIVE RESULTS IN
RA
PHASE 2B TRIAL AND HIGHEST EVER REPORTED CDAI LDA RESPONSE OVER
6 MONTHS
    * ANAPTYSBIO INC - ROSINILIMAB SAFE AND WELL TOLERATED WITH
SIMILAR ADVERSE EVENT RATES VERSUS PLACEBO
    * ANAPTYSBIO INC - ROSINILIMAB ACHIEVES STATISTICAL
SIGNIFICANCE
ON KEY SECONDARY ENDPOINTS AT WEEK 12
    * ANAPTYSBIO INC - ROSINILIMAB ACHIEVES STATISTICAL
SIGNIFICANCE
ON PRIMARY ENDPOINT AT WEEK 12
    * ANAPTYSBIO INC - TOP-LINE WEEK 12 PHASE 2 ULCERATIVE
COLITIS
DATA FOR ROSNILIMAB EXPECTED IN Q4 2025

Source text:  ID:nGNXc9Q9Gv 
Further company coverage:  ANAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))